Vanda Pharmaceuticals’ (VNDA) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report released on Tuesday,Benzinga reports. They currently have a $20.00 price objective on the biopharmaceutical company’s stock.

Separately, StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, February 5th. They set a “hold” rating on the stock.

Vanda Pharmaceuticals Stock Down 2.0 %

VNDA opened at $4.50 on Tuesday. Vanda Pharmaceuticals has a 12-month low of $3.87 and a 12-month high of $6.75. The firm has a market capitalization of $262.42 million, a P/E ratio of -14.06 and a beta of 0.69. The stock’s 50 day moving average price is $4.67 and its two-hundred day moving average price is $4.74.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.06. The business had revenue of $53.19 million for the quarter, compared to the consensus estimate of $51.00 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. As a group, analysts anticipate that Vanda Pharmaceuticals will post -1.12 earnings per share for the current year.

Insider Activity

In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of Vanda Pharmaceuticals stock in a transaction dated Friday, February 28th. The stock was bought at an average cost of $4.76 per share, with a total value of $47,600.00. Following the acquisition, the chief executive officer now owns 2,361,730 shares of the company’s stock, valued at approximately $11,241,834.80. The trade was a 0.43 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have bought 32,000 shares of company stock worth $151,180. Company insiders own 8.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Intech Investment Management LLC bought a new stake in shares of Vanda Pharmaceuticals in the 3rd quarter valued at approximately $84,000. Charles Schwab Investment Management Inc. boosted its stake in Vanda Pharmaceuticals by 0.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 596,210 shares of the biopharmaceutical company’s stock valued at $2,796,000 after buying an additional 3,473 shares in the last quarter. FMR LLC grew its position in Vanda Pharmaceuticals by 25.9% in the third quarter. FMR LLC now owns 149,739 shares of the biopharmaceutical company’s stock valued at $702,000 after acquiring an additional 30,802 shares during the period. BNP Paribas Financial Markets raised its stake in Vanda Pharmaceuticals by 1,184.6% during the third quarter. BNP Paribas Financial Markets now owns 62,238 shares of the biopharmaceutical company’s stock worth $292,000 after acquiring an additional 57,393 shares in the last quarter. Finally, Verition Fund Management LLC lifted its holdings in shares of Vanda Pharmaceuticals by 7.8% during the third quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 2,927 shares during the period. Institutional investors and hedge funds own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.